Société Générale — Director's Dealing 2020

May 7, 2020

National Storage Mechanism | Additional information

RNS Number : 2464M

Societe Generale SA

07 May 2020

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1)	Société Générale S.A.
Company dealt in	Willis Towers Watson plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	US$0.000304635 ordinary shares
Date of dealing	06/05/2020

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
Number	(%)	Number	(%)
(1) Relevant securities	103,126	0.08	8,372	0.01
(2) Derivatives (other than options)	88	0.00	14,618	0.01
(3) Options and agreements to purchase/sell	0	0.00	0	0.00
Total	*1,333,014	*1.04	22,990	0.02

* Include the holding of 1,229,800 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit USD (Note 5)
Purchase	30	187
Purchase	40	187
Purchase	30	187
Purchase	1,206	183.64
Purchase	10	183.64
Purchase	462	183.64
Sale	59	187.41
Sale	10	187.41
Sale	26	187.41
Sale	5	187.41
Sale	8	187.37
Sale	1	188.5
Sale	100	187.72
Sale	6	188.91
Sale	10	188.91
Sale	24	188.91
Sale	6	184.26
Sale	82	184.26
Sale	12	184.26
Sale	100	184.59
Sale	100	188.45
Sale	100	188.34
Sale	30	187.06
Sale	93	187.21
Sale	7	187.21
Sale	10	187.39
Sale	14	187.23
Sale	70	187.06
Sale	10	187.39
Sale	50	187.57
Sale	50	186.9
Sale	50	186.9
Sale	10	187.57
Sale	20	187.57
Sale	19	183.74
Sale	19	183.53
Sale	1,102	185.012205
Sale	214	188.18271
Sale	100	186.77
Purchase/sale	Number of relevant securities	Price per unit EUR (Note 5)
Sale	7	175
Total Purchases	1,778
Total Sales	2,524

(b)      Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit USD (Note 5)

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. If none, this

should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            No

Date of disclosure	07/05/2020
Contact name	Société Générale - Disclosure team
Telephone number	+33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

ISEFIFFEEEIDIII